Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding
Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to
reduce platelet reactivity and to prevent thrombotic events in patients treated with …
reduce platelet reactivity and to prevent thrombotic events in patients treated with …
Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments
JL Mega, T Simon - The Lancet, 2015 - thelancet.com
Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and
treat many cardiovascular disorders and, as such, are some of the most commonly …
treat many cardiovascular disorders and, as such, are some of the most commonly …
Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products
GD Anderson, LN Chan - Clinical pharmacokinetics, 2016 - Springer
Tobacco smoke contains a large number of compounds in the form of metals, volatile gases
and insoluble particles, as well as nicotine, a highly addictive alkaloid. Marijuana is the most …
and insoluble particles, as well as nicotine, a highly addictive alkaloid. Marijuana is the most …
Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy
ZY Wang, M Chen, LL Zhu, LS Yu, S Zeng… - … and clinical risk …, 2015 - Taylor & Francis
Background Coprescribing of clopidogrel and other drugs is common. Available reviews
have addressed the drug–drug interactions (DDIs) when clopidogrel is as an object drug, or …
have addressed the drug–drug interactions (DDIs) when clopidogrel is as an object drug, or …
Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties
N Ferri, A Corsini, S Bellosta - Drugs, 2013 - Springer
The P2Y 12 receptor is a key player in platelet activation and represents an effective
pharmacological target for the inhibition of platelet aggregation and prevention of …
pharmacological target for the inhibition of platelet aggregation and prevention of …
CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated …
Background—The degree to which cytochrome P450 (CYP) 2C19 genotype influences the
effectiveness of clopidogrel remains uncertain because of considerable heterogeneity in …
effectiveness of clopidogrel remains uncertain because of considerable heterogeneity in …
Pharmacokinetics and pharmacodynamics of approved and investigational P2Y12 receptor antagonists
U Schilling, J Dingemanse, M Ufer - Clinical Pharmacokinetics, 2020 - Springer
Coronary artery disease remains the major cause of mortality worldwide. Antiplatelet drugs
such as acetylsalicylic acid and P2Y12 receptor antagonists are cornerstone treatments for …
such as acetylsalicylic acid and P2Y12 receptor antagonists are cornerstone treatments for …
Smoking is associated with adverse clinical outcomes in patients undergoing revascularization with PCI or CABG: the SYNTAX trial at 5-year follow-up
Background: Cigarette smoking is a well-known risk factor for development of coronary
artery disease (CAD). However, some studies have suggested a “smoker's paradox,” …
artery disease (CAD). However, some studies have suggested a “smoker's paradox,” …
Diabetes-versus smoking-related thrombo-inflammation in peripheral artery disease
Peripheral artery disease (PAD) is a major health problem with increased cardiovascular
mortality, morbidity and disabling critical limb threatening ischemia (CLTI) and amputation …
mortality, morbidity and disabling critical limb threatening ischemia (CLTI) and amputation …
Smoker's paradox in patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
Background Prior studies have found that smokers undergoing thrombolytic therapy for ST‐
segment elevation myocardial infarction have lower in‐hospital mortality than nonsmokers, a …
segment elevation myocardial infarction have lower in‐hospital mortality than nonsmokers, a …